Ranbaxy forays into authorised generics in US with launch of Isoptin SR
Ranbaxy Laboratories has commercialised its first authorised generic product, Isoptin SR, an anti hypertensive agent, in the US market.
NEW DELHI: Pharmaceutical major Ranbaxy Laboratories on Monday said it has commercialised its first authorised generic product, Isoptin SR -- an anti hypertensive
agent -- in the US market.
The commercialisation follows an agreement with US-based FSC Laboratories, the patent holder of the original compound Verapamil SR, the company said in a statement.
"The commercialisation of Ispotin SR heralds Ranbaxy's entry into the authorised generics space. Isoptin SR, a niche value added formulation, also enhances our new drug delivery systems (NDDS) capability and our efforts with other molecules to improve patient compliance," Ranbaxy Vice-President and Regional Director North America K Venkatachalam said.
Verapamil, a calcium ion antagonist or channel blocker, is indicated for management of hypertension and angina. The generic market of Verampil SR is estimated to be about 122.2 million dollar with limited competition, it added.
agent -- in the US market.
The commercialisation follows an agreement with US-based FSC Laboratories, the patent holder of the original compound Verapamil SR, the company said in a statement.
"The commercialisation of Ispotin SR heralds Ranbaxy's entry into the authorised generics space. Isoptin SR, a niche value added formulation, also enhances our new drug delivery systems (NDDS) capability and our efforts with other molecules to improve patient compliance," Ranbaxy Vice-President and Regional Director North America K Venkatachalam said.
Verapamil, a calcium ion antagonist or channel blocker, is indicated for management of hypertension and angina. The generic market of Verampil SR is estimated to be about 122.2 million dollar with limited competition, it added.